<p>Primary care physicians Gary Ferenchick, Kate Rowland, Henry Barry and Mark Ebell want you to know about 4 new studies: the best choice of pharmacotherapy in hypertensive disorders of pregnancy, benefits and harms of intensive BP lowering, elinzanetant for therapy-induced vasomotor symptoms in women with breast cancer, and 23 year follow up of the European Prostate Cancer Screening Trial. Plus a confusing quiz question (thanks Gary!).</p><p>Links</p><p>Essential Evidence Plus: <a href="http://www.essentialevidenceplus.com"><u>www.essentialevidenceplus.com</u></a></p><p>HTN in pregnancy: <a href="https://pubmed.ncbi.nlm.nih.gov/40216176/"><u>https://pubmed.ncbi.nlm.nih.gov/40216176/</u></a></p><p>Intensive BP lowering: <a href="https://pubmed.ncbi.nlm.nih.gov/40902616/"><u>https://pubmed.ncbi.nlm.nih.gov/40902616/</u></a> </p><p>Elinzanetant for vasomotor symptoms in patients taking tamoxifen or anastrozole: <a href="https://pubmed.ncbi.nlm.nih.gov/40454634/"><u>https://pubmed.ncbi.nlm.nih.gov/40454634/</u></a> </p><p>23 year follow-up of large European prostate cancer study: <a href="https://pubmed.ncbi.nlm.nih.gov/41160819/"><u>https://pubmed.ncbi.nlm.nih.gov/41160819/</u></a></p><p><br></p>